Awaiting development: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Type

Guidance programme

HealthTech approach

HealthTech approach

Area of interest

Showing 351 to 360 of 410

TitleType
Teplizumab for delaying progression of stage 3 type 1 diabetes in people 8 years and over [TSID12403]Technology appraisal guidance
Thyroid diseaseQuality standard
Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915]Technology appraisal guidance
Tildrakizumab for treating active psoriatic arthritis [ID6724]Technology appraisal guidance
Timrepigene emparvovec for treating choroideremia [ID3916]Technology appraisal guidance
TinnitusQuality standard
Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors [TSID12064]Technology appraisal guidance
Tiratricol for treating Allan–Herndon–Dudley syndrome [ID6217]Technology appraisal guidance
Tirzepatide for managing overweight and obesity in people 12 to 17 years [ID6707]Technology appraisal guidance
Tirzepatide for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and cardiovascular disease [ID6733]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All